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1. Introduction 
Tissue engineering is a field of medicine that has experienced significant growth in 
prominence over the past three decades. Though traditional interventions exist for many 
medical maladies, tissue engineering aims to combat such disorders through the synthesis of 
body tissues and organs, resulting in functional implants. Tissue engineering takes an 
innovative approach, often utilizing autologous stem cells for tissue construction or 
materials that are biocompatible while avoiding immune rejection (Nomi et al., 2002).  
Despite its immense successes, a major hurdle still faces tissue engineering. Large volumes 
of implanted tissue are unable to stimulate the formation of necessary blood vessels 
required for their survival. In the body, naturally occurring, equivalent vascular networks 
serve vital functions in gas and nutrient exchange, metabolic processes, and waste 
expulsion. Though individual, large vessels have been successfully engineered for implant, 
it is still exceptionally difficult to fashion a stable and sustainable network of vessels for 
large volumes of tissue (Nomi et al., 2002). Neovascularization after tissue damage requires a 
level of positive and negative control that has not been successfully replicated in a 
laboratory environment to date. As such, rapid de novo synthesis of a controlled, established 
vascular network remains a challenge today. 
Angiogenesis is the morphogenic process of forming new blood vessels from pre-existing 
ones (Laschke et al., 2006; Dai and Rabie, 2007; Li and Rabie, 2007). This event plays an 
important, normal physiological role in wound healing, tissue repair, pregnancy, and 
exercise (Ferrara and Davis-Smyth, 1997), and exists in contrast to vasculogenesis (the 
formation of the every first blood vessels in the body, and especially predominant in 
embryological development). Yet, the abuse of angiogenesis, leading to an uncontrolled 
vascular formation as a consequence of epigenetic influence, nucleotide polymorphisms, or 
endocrine irregularities can also result in tumor formation (Verbridge et al., 2010). However, 
angiogenesis is clearly an activity that is central to development and tissue maintenance. 
Successful modulation of angiogenesis can have profound therapeutic outcomes for organs 
and tissues deprived of an adequate, stable vasculature. Studies from the last two decades 
have shown that the manipulation of various factors directly influences angiogenic outcome.  
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
434 
Angiogenesis requires the activity of soluble factors such as Vascular Endothelial Growth 
Factor (VEGF; outlined in the next section and in Tables 2 & 3), basic Fibroblast Growth 
Factor (bFGF), Platelet-derived Growth Factor (PDGF), Transforming Growth Factor-β 
(TGF- β) (Nomi et al., 2002; Dai and Rabie, 2007; Li and Rabie, 2007; Kanczler and Oreffo, 
2008; Bates, 2010), Keratinocyte Growth Factor (KGF) (Elia et al., 2010), Hepatocyte Growth 
Factor (HGF) (Hoot et al., 2010), Ephrin-B2 (Herbert et al., 2009), and Angiopoietin(Han et al., 
2010) (Table 1). Morphologically, angiogenesis can be attributed to endothelial cell 
migration and proliferation as well as pericyte recruitment, migration and differentiation 
(Egginton, 2010). 
 
Molecule Known Properties Citations 
Basic Fibroblast 
Growth Factor 
(bFGF) 
Stimulates activity of fibroblasts, neurons, smooth 
muscle cells, and endothelial cells; acts via tyrosine 
kinase receptors; induces production of VEGF 
during angiogenic stimulation. 
(Pepper et al., 
1992; Lee et al., 
2003; Arkudas et 
al., 2007; Jung et 
al., 2010; Wu et 
al., 2010) 
Platelet-derived 
Growth Factor 
(PDGF) 
Certain isoforms possess survival and mitogenic 
functions; implicated in tumor angiogenesis; 
compared to VEGF, PDGF: (a) has comparable 
angiogenic activity, (b) produces blood vessels with 
decreased permeability and leakage, and (c) is 
thought to produce functionally different blood 
vessels. 
(Li et al., 2010; 
Wu et al., 2010) 
Transforming 
Growth Factor β 
(TGF-β) 
Promotes and inhibits angiogenesis and tumor 
invasion via stimulation of Hepatocyte Growth 
Factor (HGF) expression. 
(Hoot et al., 2010) 
Keratinocyte 
Growth Factor 
(KGF) 
Member of FGF family; certain isoforms have been 
implicated in wound healing as well as the inhibition 
of neovascularization. 
(Wang et al., 
2010) 
Hepatocyte 
Growth Factor 
(HGF) 
Stimulates endothelial cell growth, migration, 
scatter, and elongation independently of VEGF. (Hoot et al., 2010) 
Ephrin-B2 Implicated in arterial/venous differentiation (see section: Modulation of Notch Signaling). 
(Herbert et al., 
2009) 
Angiopoietin 
Signals through Tie receptors; certain isoforms are 
angiogenic inhibitors, while others promote 
inhibition of apoptosis; Stabilize blood vessels and 
reduce leakage. 
(Han et al., 2010) 
Table 1. Notable Ancillary Growth Factors and Their Properties 
2. VEGF and its receptors: a brief overview 
In studying the development of cells, tissues, and organs, Vascular Endothelial Growth 
Factor (VEGF) has been identified as a key, though not sole, proponent of angiogenesis 
(Takahashi and Shibuya, 2005; Arkudas et al., 2007; Dai and Rabie, 2007; Yla-Herttuala, 2009; 
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Bates, 2010; Elia et al., 2010). VEGF exists in six classes (Table 2), lettered A through F, 
though the vast amount of literature concerning VEGF-A indicates that it is by far the most 
widely understood of all. VEGF-A exists in at least eight homodimeric isoforms, all 
conceived by alternative mRNA splicing(Ferrara, 2009) and differing by their amino acid 
number. Of these, VEGF121 and VEGF165 are predominant and show great promise in tissue 
engineering applications. 
 
VEGF Class Known Properties Citations 
A 
Induces proliferation of arterial, venous, and 
lymphatic vascular endothelial cells; stimulates 
monocyte chemotaxis; hematopoetic effects; eight 
isoforms in humans. 
(Ferrara, 2009) 
B May play role in atrial conduction, but not required for cardiovascular development. 
(Olofsson et al., 
1996a; Olofsson 
et al., 1996b; Aase 
et al., 2001) 
C 
Involved in embryonic angiogenesis, 
lymphangiogenesis, & lymphatic vessel maintenance; 
mitogenic for cultured endothelial cells. 
(Kukk et al., 1996; 
Orlandini et al., 
1996; Jeltsch et 
al., 1997; Yamada 
et al., 1997; 
Dumont et al., 
1998) 
D 
Thought to be involved in pulmonary development, 
endothelial cell mitogen; Function(s) still generally 
unclear. 
(Orlandini et al., 
1996; Yamada et 
al., 1997; Achen 
et al., 1998; 
Farnebo et al., 
1999) 
E 
Proteins are encoded by Orf-viruses and 
predominantly expressed in sheep, goats, and rarely 
in humans. 
(Lyttle et al., 
1994; Meyer et al., 
1999) 
F Derived from snake venom; enhances the formation of vascular fenestrations in guinea pigs. 
(Klein and 
Catargi, 2007; 
Matsunaga et al., 
2009; Yamazaki 
et al., 2009) 
Placental Growth 
Factor (PlGF) 
Induces vascular permeability; supplements VEGF 
activity during wound-healing; may enhance VEGF-
driven angiogenesis. 
(Carmeliet et al., 
2001; Adini et al., 
2002; Hattori et 
al., 2002; Luttun 
et al., 2002; 
Odorisio et al., 
2002) 
Table 2. Six General VEGF Classes 
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The binding of VEGF to any of its many receptors, such as VEGF-R1 (Flt-1) (Shibuya et al., 
1990; de Vries et al., 1992), VEGF-R2 (KDR) (Terman et al., 1991), VEGF-R3 (Flt-4) (Fitz et al., 
1997), and Neuropilin (NRP-1 and -2) (Soker et al., 1996; Soker et al., 1998; Dallas et al., 2008), 
has been shown to trigger a signaling cascade that results in the activation of angiogenesis 
(Stefanini et al., 2009). Not surprisingly, VEGF receptor and ligand placement and density 
have been implicated in the successful transmission of the signaling cascades required for 
angiogenesis (Stefanini et al., 2009). Modulating receptors and their densities appear to be a 
logical avenue for further efforts in modulating neovascularization. Further, Heparin Sulfate 
Proteoglycan (HSPG) has been implicated in the binding of VEGF to their receptors, but its 
exact function remains unclear (Ferrara et al., 2003; Lee et al., 2010). Preliminary findings 
suggest that HSPGs inhibit VEGF binding to its receptors, and consequently, angiogenic 
activity (Lee et al., 2010).  
3. Modulations to VEGF and its delivery 
Though VEGF has a significant influence on cell migration, proliferation, and vasodilation, 
the uncontrolled or sole use of VEGF in vivo has been shown to result in the disordered 
growth of blood vessels into a dense mass (hemangioma), malignant tumor angiogenesis, 
and the assembly of leaky vessels (Takahashi and Shibuya, 2005; Bates, 2010). As such, the 
fundamental function of VEGF in physiological development and maintenance, contrasted 
by its role in tumorigenesis and vessel instability, is paradoxical. In instances where VEGF 
is heterogeneously present in a microenvironment, areas of high VEGF expression 
resulted in abnormal angiogenesis. However, implanting VEGF-transfected myoblasts, 
with each cell equally producing VEGF over time, led to the formation of a stable, normal 
vascular network (Misteli et al., 2010). The latter provides a compelling case for carefully-
controlled VEGF release, distribution, and kinetics in tissue engineering applications. As 
discussed below, several current tissue-engineering efforts are positioned to resolve this 
dilemma.  
It should not be assumed that blind administration of VEGF is solely responsible for a 
successful angiogenic effort. Many studies have illustrated that the promotion of successful 
angiogenesis depends on a prolonged exposure to a low dose of VEGF (Wernike et al., 2010), 
while other studies claim that micro-environmental conditions must be taken into account 
(Ferrara and Davis-Smyth, 1997; Misteli et al., 2010). With regards to the latter, techniques 
like FACS purification (Misteli et al., 2010) and microdialysis (Hoier et al., 2010; Marcus et al., 
2010) are becoming increasingly prevalent in closely monitoring VEGF expression in the 
microenvironment. Further, many attempts at eliciting controlled angiogenesis also focus on 
coupling the properties of VEGF with certain other growth factors – most notably bFGF 
(Arkudas et al., 2007) or KGF (Elia et al., 2010) (see Table 1); stable vessels were formed when 
VEGF was combined with either of these two factors.  
There exist contradictions regarding the parameters of tissue exposure to VEGF. In one 
comparison, a study highlighting growth factor implementation in orthopedic applications 
suggested that VEGF delivery for over 14 days may have interfered in the vascularization 
during bone healing and restoration (Wernike et al., 2010). This suggestion challenges an 
argument that a longer VEGF exposure (of approximately one month) was necessary for the 
production of stable, but leaky, vessels as brief exposure to VEGF (less than 15 days) 
resulted in the formation of unstable vessels. Further, these vessels actually degenerated 
after VEGF delivery cessation (Tafuro et al., 2009). Disparities such as this are common in the 
 
Angiogenesis and Vascularity for Tissue Engineering Applications 
 
437 
literature and demonstrate the sheer complexity of VEGF activity in various tissue 
environments. 
The view that successful VEGF delivery and angiogenic response are strictly dose-
dependent is challenged by factors such as delivery kinetics, which appear to be critical for 
proper vasculature (Borselli et al., 2010; Wernike et al., 2010). For instance, a characteristic 
problem with the bolus delivery of VEGF is the outcome of variable systemic effects 
(Matoka and Cheng, 2009) such as haemorrhage, hypotension, or flu-like symptoms 
(Benjamin et al., 1999). This method of delivery also fails to achieve the prolonged supply of 
physiological low dose of VEGF necessary to produce a mature, lasting vascular network. 
The lack of lasting vessel formation observed in many therapeutic trials is probably due to 
difficulties in the delivery of VEGF, a growth factor with an apparently narrow therapeutic 
window (Hariawala et al., 1996; Lee et al., 2000; Dor et al., 2003; Ozawa et al., 2004), in the 
optimal time and dose for maintaining sufficient vascularity.  
A need exists for biomaterials or stable scaffolds that enable slow, sustained VEGF 
release(Rocha et al., 2008) for a predictable and functional outcome. Studies in different 
laboratories have indicated that incorporation of growth factor into slow-release polymer 
formulations could present a means for better control of dose, location, and duration of 
active signals in tissue (Edelman et al., 1991; Lee et al., 2000; Sheridan et al., 2000; Ehrbar et 
al., 2004). The kinetics of VEGF delivery today depends on the physical properties (such as 
cross-linking and porosity, for instance) of biocompatible conduits such as fibrin-gels 
(Ehrbar et al., 2004; Arkudas et al., 2007), gelatin microparticles (Patel et al., 2008), collagen / 
fibronectin hydrogels (Glotzbach et al., 2010), and PLG(A) scaffolds (Murphy et al., 
2000)(Rocha et al., 2008; Matoka and Cheng, 2009; Borselli et al., 2010; Golub et al., 2010). 
Moreover, transfecting or transducing developing cells (muscle precursor cells or myoblasts, 
for instance) with VEGF and subsequently injecting them into a site can also provide a 
steady, longer-term delivery of the growth factor (Misteli et al., 2010).  
Once VEGF is coupled with a delivery conduit, a more intricate approach to controlling 
VEGF delivery involves modifying the factor itself. Extensive delivery-mechanics research 
was conducted with the isoform VEGF121. Though VEGF121 is initially confined within a 
biomaterial (such as a fibrin-gel matrix) upon implant, plasmin and metalloproteinase 
degradation of the implant over time allows for the rapid, free diffusion of VEGF121 into the 
whole body environment (Ehrbar et al., 2004), potentially resulting in angiogenesis that may 
not be localized. Additionally, the short biological half-life of VEGF impedes its use in long-
term applications. A synthetic variant of VEGF121, known as TG-VEGF121, cross-links to 
fibrinogen by the transglutaminating activity of factor XIII during fibrin-gel polymerization. 
This covalently tethered TG-VEGF121 is protected from rapid diffusion. Gradual degradation 
of the fibrin-gel by local fibrinolytic activities results in a local liberation of low levels of TG-
VEGF121 into tissue. Experimental animal models have shown that fibrin-conjugated TG-
VEGF121 produced more structurally stable vessels than VEGF121 while avoiding vascular 
leakage (Ehrbar et al., 2004; Ehrbar et al., 2008).  
4. Hypoxia-mediated control and modulation of notch signaling 
Hypoxia presents another means of employing direct control on VEGF and ancillary 
angiogenic factors. In the low-oxygen environments of normal muscle, VEGF mRNA 
experiences decreased degradation and increased expression (Ikeda et al., 1995; Levy et al., 
1995; Levy et al., 1996; Tang et al., 2004), though severely hypoxic settings will actually 
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impede VEGF up-regulation (Milkiewicz et al., 2004). VEGF mRNA stability is made 
possible by its interaction with HuR, a complex that binds and stabilizes RNAs, 
consequently regulating gene expression (Levy et al., 1998). The increase in VEGF 
production can be attributed to the Internal Ribosome Entry Site (IRES), which is 
accountable for efficient factor synthesis under hypoxic conditions (Stein et al., 1998). Other 
proteins can also impact VEGF efficiency and activity. Control of expressed VEGF lies with 
ORP150 (oxygen regulated protein), a chaperone that transports VEGF from the cell’s 
endoplasmic reticulum to the Golgi apparatus (Kuwabara et al., 1996; Ozawa et al., 2001). An 
increase in ORP150 levels correlates with an increased production of VEGF during hypoxia 
(Ozawa et al., 2001). Further, Hypoxia-inducing factor (HIF) is responsible for activating the 
transcription of genes associated with neovascularization (Covello and Simon, 2004; 
Ramirez-Bergeron et al., 2006). These proteins represent points of control for VEGF 
modulation. 
Because angiogenesis is the synthesis of vasculature from existing vessels, constant 
remodeling and modification of vessels takes place in vivo. Existing endothelial cells, such as 
stalk and tip cells, have receptors that respond to environmental conditions like hypoxia, in 
which Notch signaling (driven by VEGF-A presence) is most prevalent. The presence of 
VEGF-A leads to an increase in the presence of Delta-like Ligand 4 (DLL4), a major Notch 
ligand. It is believed that Notch signaling modulates the ratio of VEGF to its receptors 
through the inhibition of VEGF-R2. 
Manipulation of the Notch signaling pathway presents another means of controlling 
angiogenesis. Cao, et al., discussed the role of Notch signaling in modulating VEGF activity, 
resulting in effective pruning and branching of vascular vessels (Cao et al., 2009; Cao et al., 
2010). Activation of the Notch signaling pathway inhibits VEGF signaling by down-
regulating the VEGF receptor synthesis. With fewer available receptors for free VEGF to 
bind, endothelial cell proliferation is effectually curbed. This process occurs at the cellular 
level of the lining endothelium, a major component of vascular vessels, and vascular growth 
in any particular direction is controlled. 
5. Applications in regenerative medicine: notable case studies 
Recent advances in understanding the angiogenic process and isolating potent and specific 
angiogenic growth factors prompted their therapeutic usage. Evidence that VEGF is a 
specific endothelial cell growth factor suggested its potential in therapeutic angiogenesis. 
Injection of the VEGF165 protein enhanced revascularization of rabbit ischemic hindlimbs 
(Takeshita et al., 1994). VEGF treatment induced collateral vessel formation, endothelium-
dependent blood flow and tissue perfusion. VEGF has been tested for potential beneficial 
effects on wound repair in diabetic animal models (Greenhalgh et al., 1990; Tsuboi and 
Rifkin, 1990; Frank et al., 1995). The growth factor treatment regimens accelerated 
granulation, tissue formation, and wound closure. However, due to the high clearance 
and/or degradation of the proteins from the administration site, topically administered 
growth factors would require high dosages and frequent delivery.  
An alternative strategy for therapeutic angiogenesis is gene therapy using recombinant 
angiogenic growth factors. The first study using VEGF165 cDNA was performed by gene 
transfer into the iliac artery of an ischemic hindlimb of a rabbit (Bauters et al., 1994; 
Takeshita et al., 1996). VEGF protein was expressed at the site of injection, augmenting the 
formation of collateral vessels. Subsequently, intramuscular gene transfer of VEGF cDNA 
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was used in a similar model with similar results (Asahara et al., 1996). This technique was 
further employed in patients with peripheral vascular disease and critical limb ischemia 
(Isner et al., 1996). Clinical trials showed significant improvement in collateral blood flow, 
healed ischemic ulcers, and most importantly, salvage of limbs in patients in whom 
amputation was imminent (Isner, 1998; Isner and Takayuki, 1998). VEGF protein and cDNA 
have been used for coronary revascularization, resulting in improved myocardial perfusion 
and increased collateral density (Isner and Losordo, 1999). 
As previously discussed, a successful angiogenic outcome is not solely attributed to VEGF 
implementation alone (discussed in Section 3 and Table 1). Wilcke, et al., showcased the 
coupling of VEGF with bFGF in a fibrin dermal substitute (Wilcke et al., 2007). This led to a 
marked improvement in factor delivery, with a notable, prolonged release and resulted in a 
higher density of newly developed vessels in in vivo murine models. Concurrently, an in 
vivo experiment performed by Zacchigna, et al., studied the effect of a VEGF and 
Angiopoietin 1 (Ang 1) combination (delivered via an adeno-associated viral vector, for 
long-term protein production and release) on the muscle blood flow (MBF) and vascular 
permeability of rat skeletal muscle (Zacchigna et al., 2007). The grouping elicited a marked 
increase in both resting MBF and perfusion post exercise stimulation. To contrast, VEGF 
expression alone did not enhance the resting MBF and actually reduced tissue perfusion 
after exercise.  
Elcin, et al., researched in vitro release kinetics and in vivo angiogenic effects of human 
VEGF-loaded PLGA sponges in rats (Elcin and Elcin, 2006). When compared with control 
sponges (containing no factor) and bolus injections of VEGF, the use of VEGF-loaded PLGA 
sponges led to the establishment of neovascularized sites suitable for tissue engineering 
purposes. Patel, et al., who utilized VEGF-loaded gelatin microparticles infused in 
biodegradable composite scaffolds, outlined another notable attempt in VEGF delivery 
modulation in the field of orthopedics (Patel et al., 2008). Findings suggested that 
modulating the degree of gelatin cross-linking could affect VEGF release into the 
microenvironment and, consequently, angiogenic outcome. Ennett, et al., studied the 
temporally regulated delivery of VEGF in vivo, hypothesizing that the means of VEGF-
loading into a delivery scaffold would have an impact on the factor release kinetics (Ennett 
et al., 2006). They compared (a) VEGF loaded directly into a PLG scaffold with (b) VEGF pre-
encapsulated in PLG microspheres that were later used to fabricate a PLG scaffold. Though 
pre-encapsulated VEGF microspheres further delayed the factor’s release into the 
surrounding environment, this approach produced a desirable angiogenic outcome, with 
significant local angiogenesis and negligible systemic effects. 
Pre-encapsulation of VEGF by nanoparticles or microspheres has also been investigated in 
conjunction with Matrigel hydrogels, PLGA-, and collagen-scaffolds. While it is clear that 
encapsulation protects the factor(s) within the nanoparticles and microspheres, it also offers 
a mechanism of controlled release – especially ideal for a potent angiogenic factor like 
VEGF. Even though pre-encapsulated VEGF-loaded PLGA scaffolds performed better than 
similarly loaded Matrigel hydrogels (with respect to release profiles in a saline solution; also 
in comparison with free VEGF) in vitro, both of the loaded delivery conduits improved 
angiogenesis in vivo. An increase in both endothelial cell counts and red blood cells was 
noted at the sites of implantation (des Rieux et al., 2010). Further, VEGF-loaded PLGA 
microspheres combined with collagen elicited strong enhancements to vascular sprouting 
and activation of endothelial cells in vivo and in vitro, respectively (des Rieux et al., 2010).  
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The idea of optimizing delivery agents combined with the notion that co-factor usage is 
ideal for neovascularization resulted in an experiment that analyzed the co-implementation 
of VEGF with FGF-2 via an acellular collagen scaffold implant (Nillesen et al., 2007). An 
implant containing both factors resulted in the highest vessel density and the most mature 
blood vessels (characteristics of an enhanced, stable vasculature) in a rat model when 
compared with scaffolds containing either of the factors alone or no factor at all.  
6. Conclusion 
A significant challenge facing tissue engineering lies in eliciting controlled 
neovascularization. Controlled neovascularization can have a profound impact in vessel and 
organ synthesis, as well as in the treatment of damaged tissues. Many current attempts for 
such control entail the use of VEGF. Attempts at fabricating an ordered vascular network 
include changes to VEGF through structural modification, the employment of strategies 
controlling its release, and coupling VEGF to other growth factors. 
Yet, despite the promises shown by VEGF, significant obstacles remain. Many researchers 
propose that use of growth factors alone will not ensure stable angiogenesis. Rather, a 
combination of growth factors (VEGF and bFGF, for example), delivery methods, and 
modulation of inflammatory responses (via fibroblast, macrophage, cell-adhesion molecule 
and cytokine manipulation, for instance) and pathways (such as hypoxia and Notch) are 
thought to facilitate adequate vessel fabrication and stability. 
Additionally, investigation into the mechanisms of cellular crosstalk is necessary to better 
understand angiogenesis in general. Moreover, the refinement and implementation of 
microenvironment monitoring technologies are vital in ensuring proper vascular 
development. Such technologies would enable researchers to closely study the impact of 
gross- or modulated-release of growth factors on the delicate balance required for vascular 
formation and branching. 
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